rttnews.com
Cure8 news brief
Why This Matters
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials, this strategy could offer another option for patients not controlled by a single biologic.
Who Should Pay Attention
Adults with moderate–severe Crohn's disease, especially those who have failed one or more biologics; clinicians treating IBD; researchers and drug developers following combination biologic strategies.
Study Snapshot
Story typeResearch news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
AbbVie reported Phase 2a TARGET-CD results for ABBV-466, a combination therapy pairing risankizumab (an IL-23 inhibitor, marketed as Skyrizi) with trosunilimab (an investigational α4β7 inhibitor).
In the 300‑patient trial, ABBV-466 showed higher endoscopic remission rates at Weeks 12 and 24 versus either monotherapy, and company analyses suggested gene-expression changes consistent with tissue repair and barrier restoration. Serious adverse events were similar across groups but were reported in about 10% of participants on ABBV-466.
ABBV-466 is investigational and not approved; these are mid-stage results presented at UEGW.
Keep In Mind
These are Phase 2a results presented at a conference and reported by the company; ABBV-466 remains investigational and needs confirmation in larger, later‑stage trials. Safety signals appear broadly similar across arms here, but longer follow-up and independent peer review will be important.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationrttnews.com
AuthorsTajSabreen Ahamed
Indexed viaBing News
Source typeWeb article
PublishedOct 19, 2026, 2:58 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
Ex Vivo Comparison Of Combination Versus Single Therapeutic Pathway Inhibition In Human Intestinal Mucosa From Patients With Inflammatory Bowel Disease
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...